Brought to you by 
Acclarent closes $26mm Series D after pulling IPO
09 Mar 2021
Executive Summary
Following last month's withdrawal of its IPO due to the financial climate, Acclarent (endoscopic surgical devices for chronic sinusitis) looked to venture investors again and raised $26mm through its Series D round. New backer Johnson & Johnson Development Corp. joined returning shareholders New Enterprise Associates, Delphi Ventures, Versant Ventures, and Meritech Capital Partners.
Deal Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acclarent closes $26mm Series D after pulling IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice